CVRdatabase
Menu

Vesper Bio ApS

Private limited companyCVR 32879861København KActive

Vesper Bio ApS is a private limited company, based in København K, active in research and experimental development on natural sciences and engineering, founded in 2010. Equity was negative at the end of 2025 (−DKK 227.4m). The company made a loss in both 2024 and 2025, most recently DKK 48.2m.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profit−DKK 36.4m+45.8% vs. 2024
Net profit−DKK 48.2m+27.5% vs. 2024
Equity−DKK 227.4m−26.9% vs. 2024
Employees8latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss got smaller: from DKK 66.5m to DKK 48.2m (2024 → 2025).

Management and owners, last 24 months

  • New in management: Jacob Falck Hansen (ceo, 25/06/2025).
  • Stepped down: Paul Brian Little (ceo, 25/06/2025).

Registrations, last 24 months

  • 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 250m−DKK 200m−DKK 150m−DKK 100m−DKK 50mDKK 0202020212022202320242025
EquityNet profit
Financial figures for Vesper Bio ApS
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Gross profit−6,780−13,499−31,620−67,586−67,244−36,446+45.8%
Operating profit (EBIT)–−14,946−32,959−71,994−72,836−42,491+41.7%
Profit before tax−7,955−16,471−36,860−80,772−86,853−62,786+27.7%
Net profit−7,955−16,471−36,860−52,563−66,506−48,201+27.5%
Total assets5,8845,27525,53232,18169,84965,946−5.6%
Equity−6,831−23,303−60,163−112,726−179,232−227,433−26.9%
Liabilities12,71528,57885,695144,907249,081293,379+17.8%
Cash and cash equivalents5,6015,06624,5931,24221,02547,238+124.7%
Average number of employees101698−11.1%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 70m−DKK 60m−DKK 50m−DKK 40m−DKK 30m−DKK 20m−DKK 10mDKK 0202020212022202320242025
Gross profitMedian, the industry (431 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 227.4m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Vesper Bio ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202512/03/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202415/05/2025The companyPDFXBRL
202301/01/2023 – 31/12/202305/03/2024The companyPDFXBRL
202201/01/2022 – 31/12/202227/03/2023The companyPDFXBRL
202101/01/2021 – 31/12/202117/03/2022The companyPDFXBRL
202001/01/2020 – 31/12/202025/03/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
024681009/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/2608/26
Employees

Position in the industry

431 companies in the database

Comparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.

Gross profit−DKK 36.4mNo. 414 of 421
Better than 2% of the companies in the industry
Equity−DKK 227.4mNo. 428 of 431
Better than 1% of the companies in the industry
Number of employees8No. 158 of 431
Better than 63% of the companies in the industry

Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.

DKK 100kDKK 2.5mDKK 63.4mDKK 1.6bnDKK 13.7bn
Distribution of gross profit for 250 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 69,717of 69,742
Better than 0%
No. 69,958of 69,964
Better than 0%
Same industry and fewer than 20 employees329 companies in the comparison
No. 320of 323
Better than 1%
No. 329of 329
Better than 0%
Companies that are between 15 and 29 years old24,910 companies in the comparison
No. 24,773of 24,791
Better than 0%
No. 24,904of 24,909
Better than 0%
All companies of type ApS66,508 companies in the comparison
No. 66,355of 66,379
Better than 0%
No. 66,499of 66,505
Better than 0%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Research and experimental development on natural sciences and engineering
Gross profit
  1. Vesper Bio ApS−DKK 36.4m
  2. Carlsberg A/SDKK 40.2bn
  3. Zealand Pharma A/SDKK 9.2bn
Net profit
  1. Vesper Bio ApS−DKK 48.2m
  2. Carlsberg A/SDKK 7bn
  3. Zealand Pharma A/SDKK 6.5bn
Equity
  1. Vesper Bio ApS−DKK 227.4m
  2. Carlsberg A/SDKK 30.7bn
  3. Zealand Pharma A/SDKK 14.8bn
Employees
  1. Vesper Bio ApS8
  2. Carlsberg A/S107
  3. Zealand Pharma A/S569

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Lundbeckfonden66.67%
  • 75PMK Holding ApS20%
Vesper Bio ApS

Management

1 active registrations

Executive management

Executive management at Vesper Bio ApS
NameRoleAppointed
Jacob Falck HansenCEO25/06/2025
Founders
75PMK Holding ApS
Former management (3)
Former management at Vesper Bio ApS
NameRoleAppointedResigned
Anders NykjærCEO19/04/201030/05/2013
Christian Ellebæk EllingCEO30/05/201330/09/2018
Paul Brian LittleCEO01/10/201825/06/2025

Signing rule: Selskabet tegnes af 1 direktør alene.

Address and production units

1 active production units

Hauser Plads 10
1127 København K

København Municipality · Postcode 1127

Production units
Production unitAddressEmployeesP number
Vesper Bio ApSHauser Plads 10, 4, 1127 København K81015994513

Purpose

Selskabets formål er at drive forsknings- og udviklingsvirksomhed rettet mod udvikling af lægemidler til behandling af hjernesygdomme, diabetes, diabetes-relaterede metaboliske, sygdomme, fedme og/eller fedmerelaterede sygdomme, samt at udføre aktiviteter, der er forbundet hermed.

The purpose is quoted from the register in Danish.

Changes year by year

32 registered events
20261 changeaccounts 1
  • Annual report for 2025 published
20254 changesmanagement 2 · accounts 1 · industry 1
  • Jacob Falck Hansen appointed ceo
  • Paul Brian Little stepped down as ceo
  • Annual report for 2024 published
  • Industry changed to Research and experimental development on natural sciences and engineering (721000)
20243 changesaddress 2 · accounts 1
  • Moved to Hauser Plads 10, 4, 1127 København K
  • Annual report for 2023 published
  • Moved to Gammel Kongevej 11, 1, 1610 København V
20232 changesname 1 · accounts 1
  • Name changed from INSUSENSE ApS to Vesper Bio ApS
  • Annual report for 2022 published
20221 changeaccounts 1
  • Annual report for 2021 published
20211 changeaccounts 1
  • Annual report for 2020 published
20191 changeaddress 1
  • Moved to Scherfigsvej 7, 2100 København Ø
20182 changesmanagement 2
  • Paul Brian Little appointed ceo
  • Christian Ellebæk Elling stepped down as ceo
20173 changescapital 1 · ownership 2
  • Share capital changed from 289,211 DKK to 355,952 DKK
  • 75PMK Holding ApS registered as owner (20%)
  • 75PMK Holding ApS is no longer registered as owner
20155 changescapital 1 · ownership 4
  • Share capital changed from 222,470 DKK to 289,211 DKK
  • 75PMK Holding ApS registered as owner (25%)
  • LUNDBECKFONDEN registered as owner (66.67%)
  • LUNDBECKFONDEN is no longer registered as owner
  • 75PMK Holding ApS is no longer registered as owner
20136 changesaddress 1 · capital 2 · management 2 · ownership 1
  • Moved to Scherfigsvej 7, 2100 København Ø
  • Share capital changed from 88,988 DKK to 222,470 DKK
  • Christian Ellebæk Elling appointed ceo
  • Anders Nykjær stepped down as ceo
  • LUNDBECKFONDEN registered as owner (50%)
  • Share capital changed from 374,939 DKK to 88,988 DKK
20103 changesfounded 1 · management 1 · ownership 1
  • Registered as INSUSENSE ApS
  • Anders Nykjær appointed ceo
  • 75PMK Holding ApS registered as owner (33.33%)

Related companies

Same industry in København

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction